Epigenomics Market Size was valued at USD 1.72 Billion in 2022 and is projected to grow from USD 1.98 Billion in 2023 to USD 7.04 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 15.12% during the forecast period (2023 - 2032). Increasing research in epigenetics, and rising incidence of chronic diseases are the key market drivers enhancing the market growth.
March 2024: Thermo Fisher Scientific has introduced a new set of epigenomics kits in March 2024, aimed at enhancing the accuracy and efficiency of research on DNA methylation and histone modification, thereby facilitating the acquisition of high-quality data.
February 2024: Illumina has introduced AI-driven epigenomic analysis tools in February 2024, utilizing machine learning algorithms to provide deeper insights into epigenetic modifications, aiming to accelerate the discovery of biomarkers and therapeutic targets through more precise data analysis capabilities.
April 2024: Merck KGaA has announced a partnership with a research institute to develop novel epigenetic drugs targeting histone modifications, aiming to discover new therapeutic approaches for cancer and other diseases by modulating epigenetic pathways.
Increasing research in epigenetics is driving the market growth
The topic of epigenetics is experiencing exponential expansion in research, which is a significant factor driving the market. The study of heritable modifications in gene expression that take place without changing the underlying DNA sequence, or epigenetics, has piqued the interest of researchers, physicians, and business leaders alike. Several reasons, each contributing to the advancement of knowledge and applications in this emerging subject, have spurred this spike in research activity.
The primary motivation behind the surge in interest in epigenetics research has been the promise of deciphering the complex mechanisms regulating gene expression. As the intricacy of diseases and developmental processes becomes more apparent that genetics alone cannot account for, researchers are turning to epigenetics to better understand the subtle molecular shifts that govern gene expression. There is a race to find epigenetic markers that can help with early detection, prognosis, and therapy stratification because of the potential to understand the epigenetic foundation of diseases like cancer, neurological disorders, and cardiovascular issues.
The idea of customizing medical interventions for individual patients, which is the foundation of personalized medicine, has served as a strong motivator for the growth of epigenetics research. Epigenetic changes can function as dynamic markers of an individual's exposure to environmental stimuli, lifestyle decisions, and disease development. This special relationship between the environment and the DNA provides a way to create customized treatment and diagnostic plans. The potential of epigenetic biomarkers to forecast a person's vulnerability to diseases and to tailor treatment plans for the best results is being actively investigated by researchers.
Together, efforts from academic institutions, research centers, and business sectors have helped to propel the field of epigenetics research forward. The lines between disciplines such as genetics, bioinformatics, and molecular biology have become hazier due to interdisciplinary collaborations, which have encouraged a comprehensive approach to solving challenging biological problems. Furthermore, cross-sector collaborations between academic institutions and biotechnology firms have sped up the process of turning research results into marketable goods, which has accelerated the creation of cutting-edge epigenetic diagnostics and treatments.
The scientific community's and the general public's increased understanding of epigenetics has sparked interest and curiosity, which is propelling future research efforts. The public's desire for developments in the field of epigenetics has been stoked by popular science publications, documentaries, and media coverage that emphasize the possible societal effects of this science. Public and commercial funding for epigenetics research has increased as more people realize how important epigenetics is to health and wellbeing. This has given researchers the tools they need to better understand the complexities of epigenetic control. Thus, driving the Epigenomics market revenue.
The Epigenomics Market segmentation, based on product type, includes reagents, kits, enzymes and others. The kits segment dominated the market in 2022. Specialized kits are in more demand as a result of the growing interest in epigenetics research in a number of scientific fields, including developmental biology, neurology, cancer, and genetics. These kits provide scientists with the tools and techniques they need to investigate epigenetic modifications such as histone modifications and DNA methylation.
The Epigenomics Market segmentation, based on technology, includes DNA methylation, histone methylation, histone acetylation, microRNA modification, large non-coding RNA, chromatin structures and others. The DNA methylation category generated the most income in 2022. Anomalies related to DNA methylation are commonly seen in many forms of cancer, and they are typically linked to the development and spread of tumors. There is a growing need for DNA methylation analysis methods and services as a result of researchers and clinicians use these markers more often for cancer diagnosis, prognostics, and therapy choices.
The Epigenomics Market segmentation, based on application, includes pharmaceutical and diagnostics. The pharmaceutical category generated the most income in 2022. The initiation and spread of cancer are significantly influenced by epigenetic changes. Epigenetic medicines, like histone deacetylase inhibitors and DNA methyltransferase, are being developed by pharmaceutical companies to specifically target the epigenetic modifications linked to different types of cancer. These tailored medicines present a fresh method of treating cancer and have demonstrated potential in clinical trials.
Figure 1: Epigenomics Market, by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Epigenomics Market dominated this market in 2022 (45.80%). The US-based pharmaceutical behemoth Pfizer has made investments in the research and development of epigenetic drugs. The FDA has approved Daurismo (glasdegib), their medication, as an epigenetic treatment for acute myeloid leukemia. This demonstrates the region's leadership in the commercialization of epigenetic medications. Further, the U.S. Epigenomics market held the largest market share, and the Canada Epigenomics market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: EPIGENOMICS MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Epigenomics market accounts for the second-largest market share. European researchers are actively involved in regional and worldwide cooperation projects. Networks that enable cross-border cooperation, data exchange, and resource pooling are the European Epigenomics Network (EpiGeneSys) and the European Cooperation in Science and Technology (COST). These partnerships increase the influence of European epigenomics research. Further, the German Epigenomics market held the largest market share, and the UK Epigenomics market was the fastest growing market in the European region.
The Asia-Pacific Epigenomics Market is expected to grow at the fastest CAGR from 2023 to 2032. Japan's pharmaceutical industry is expanding rapidly, and companies like Eisai and Takeda are actively engaged in epigenetic drug development. For example, Tazemetostat, an epigenetic drug developed by Epizyme in collaboration with Eisai, has been approved for the treatment of certain types of lymphoma. This illustrates how the APAC pharmaceutical industry is contributing to the growth of the epigenomics market. Moreover, China’s Epigenomics market held the largest market share, and the Indian Epigenomics market was the fastest growing market in the Asia-Pacific region.
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Epigenomics market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Epigenomics industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Epigenomics industry to benefit clients and increase the market sector. In recent years, the Epigenomics industry has offered some of the most significant advantages to medicine. Major players in the Epigenomics market, including Novartis AG, Abbott Laboratories, Abcam plc, Merck KGaA, Thermo Fisher Scientific Inc., Zymo Research Corporation, Illumina Inc., Agilent Technologies Inc., Epizyme Inc., Boehringer Ingelheim International GmbH, Bayer AG, Epigenomics, and other players and others, are attempting to increase market demand by investing in research and development operations.
Thermo Fisher Scientific Inc., also known as Thermo Fisher, is a supplier of tools for medicine, analytical equipment, consumables and reagents, software, and services for handling difficult analytical problems in clinical, research, and diagnostic labs. It provides answers for flow cytometry, synthetic biology, and cellular biology. Technologies for mass spectrometry, genetic sequencing, electron microscopy, protein, and molecular biology research are among the company's offerings.
The organization provides services to government agencies, academic and research institutions, pharmaceutical and biotech companies, clinical diagnostic labs, and the environmental, industrial quality, and process control sectors. In the Americas, Asia-Pacific, and Europe, it distributes its goods and services through third-party distributors, e-commerce, and direct sales representatives. The US town of Waltham, Massachusetts is home to Thermo Fisher's headquarters.
Agilent Technologies Inc. (Agilent) offers consumables, software, reagents, instruments, and services for a full range of laboratory workflow needs. Among its product offerings are automation systems, microarray solutions, gas and liquid chromatography systems and components, clinical and diagnostic tests, and liquid chromatography systems and components. The business provides services to the biotechnology, pharmaceutical, chemical and energy, food, environmental and forensics, contract research organizations (CROs), and contract manufacturing organizations (CMOs) industries.
Agilent uses a direct sales staff, distributors, manufacturers' representatives, resellers, and online sales to advertise its goods. The US, UK, Denmark, Germany, Italy, Japan, Malaysia, China, Singapore, and Australia are among the countries where it maintains manufacturing and research & development facilities. The US city of Santa Clara, California, is home to Agilent's headquarters.
Key Companies in the Epigenomics Market Include
Epigenomics Industry Developments
February 2022: A study on solid tumor cancer funded by the National Cancer Institute (NCI), a branch of the National Institutes of Health, reported by Zenith Epigenetics Ltd. included the first patient to receive a dose of ZEN-3694, a BET inhibitor, plus OPDIVO and YERVOY, two of Bristol Myers Squibb's PD-1 immune checkpoint inhibitors.
February 2022: Dovetail Genomics and Element Biosciences, Inc., creators of a novel and innovative DNA sequencing platform, partnered to showcase Dovetail's proximity ligation-based next-generation sequencing (NGS) library prep solutions on Element's AVITI System.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 1.72 Billion |
| Market Size 2023 | USD 1.98 Billion |
| Market Size 2032 | USD 7.04 Billion |
| Compound Annual Growth Rate (CAGR) | 15.12% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Technology, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Novartis AG, Abbott Laboratories, Abcam plc, Merck KGaA, Thermo Fisher Scientific Inc., Zymo Research Corporation, Illumina Inc., Agilent Technologies Inc., Epizyme Inc., Boehringer Ingelheim International GmbH, Bayer AG, Epigenomics, and other players. |
| Key Market Opportunities | ·        Investment and Funding |
| Key Market Dynamics | ·        Diagnostic and Therapeutic Potential |
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
